Company · Private
Trellis Bioscience, Inc.
Key figures
- SEC number
- 1162015
Source: SEC EDGAR filings and company facts; checked 22 Oct 2026
About
US biopharmaceutical company developing monoclonal antibody therapies for infectious diseases.
Rounds and raises
21 Oct 2026
Form D: $4M sold, Biotechnology SEC
21 Oct 2026
Form D: $1M sold, Biotechnology SEC
21 Oct 2026
Form D: $1M sold, Biotechnology SEC
21 Oct 2026
Form D: $23M sold, Biotechnology SEC
15 May 2026
Form D: $6M sold, Biotechnology SEC
Source: SEC EDGAR Form D and the linked articles. All raises this week
Questions and answers
- What does Trellis Bioscience, Inc. do?
- US biopharmaceutical company developing monoclonal antibody therapies for infectious diseases.
With a free account
A free account opens 10 full pages a month and lets you follow this page: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.
Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.